Logo

Eisai and Biogen’s Leqembi (Lecanemab) Receives the NMPA’s Approval for the Treatment of Alzheimer’s Disease

Share this
Eisai

Eisai and Biogen’s Leqembi (Lecanemab) Receives the NMPA’s Approval for the Treatment of Alzheimer’s Disease

Shots:

  • The approval was based on the P-III (Clarity AD) trial evaluating the safety & efficacy of Leqembi (10mg/kg, Q2W, IV) vs PBO in patients (n=1,795), randomized in a ratio 1:1, with early AD at 235 sites across North America, Europe & Asia. The 1EP of the study includes change in CDR-SB at 18mos., global cognitive & functional scale & 2EPs includes change in amyloid PET at 18mos.
  • The results showed a 1.21 vs 1.66 change in CDR-SB with a clinical decline on the global cognitive & functional scale along with a mean change in the PET sub-study of -55.5 vs 3.6
  • Leqembi is a humanized anti-soluble aggregated Aβ mAb that selectively binds to Aβ plaque components, reducing Aβ protofibrils & plaques in the brain

Ref: EISAI Image: EISAI

Related News:- Eisai to Launch Leqembi (Lecanemab) in Japan for the Treatment of Alzheimer’s Disease (AD)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions